



EP Publications

a service of WWMR, Inc.

Success Through Experience

This new EP Publication:

- Projects the number of patients with key conditions associated with peripheral neuropathy in 2007 and 2012 - diabetes, HIV/AIDS and chemotherapy treatment
- Reveals vital differences between novel compounds in development to treat peripheral neuropathy
- Uncovers the factors that will drive the growth of the emerging peripheral neuropathy market
- Predicts the commercial potential for current and upcoming drug classes in individual country markets - U.S., France, Germany, Italy, Spain, UK and Japan
- Forecasts the value (in USD) of the peripheral neuropathy market, by drug class, by condition, and by country, in 2007 and 2012

**Providing an
Enhanced Perspective...**

On

**Worldwide
Peripheral
Neuropathy**

Emerging Market & Product Assessment

Author:

Sophia K. Layne, M.S.

Contributors:

Deborah Dauber, Ph.D.

Tony Hung

About WWMR, Inc.

WWMR, Inc., is a leading marketing research and strategic consulting firm with global capabilities. Since 1994, WWMR, Inc., has provided over 450 high-quality, insightful proprietary studies to clients in the pharmaceutical, biotech, medical device, and diagnostics industries worldwide. Using primary and secondary research methodologies, WWMR, Inc., provides market opportunities and product assessments, competitive intelligence, forecasts, population projections, pre-launch product planning, post-launch product monitoring, product pricing strategy, database products, and on-site information center management. Enhanced Perspective Publications (EP Publications) is the multi-client service of WWMR, Inc.

WPN1103P1

EP Publications

a service of WWMR, Inc.

2929 Campus Drive, Suite 200 ■ San Mateo, CA 94403 ■ Toll free (888)947-2339 ■ Fax (650)312-1570 ■ EPPUB@WWMR.com ■ www.WWMR.com



EP Publications

a service of WWMR, Inc.

Providing an Enhanced Perspective...

WORLDWIDE PERIPHERAL NEUROPATHY

An Emerging Worldwide Market

Currently, there are no treatments commercially available to effectively prevent, reduce, or reverse damage to peripheral nerves, or peripheral neuropathy. By 2012, there will be over 1.5 million individuals in the seven major pharmaceutical markets – U.S., France, Germany, Italy, Spain, UK, and Japan who suffer from peripheral neuropathy caused from a wide array of factors, including certain major medical conditions (e.g., diabetes, HIV/AIDS) and chemical toxicity (e.g., chemotherapy treatment of cancer).

Growing Unmet Need

Peripheral neuropathy is currently managed primarily through controlling the cause of the damage – for diabetes and HIV/AIDS patients, this represents treating the diseases, while for cancer patients, this means limiting doses of chemotherapy or tolerating significant pain or loss of sensation.

Effective prevention and treatment of peripheral neuropathy would:

- Improve quality of life for patients with diabetes or HIV/AIDS by providing relief from progressing levels of pain symptoms
- Facilitate full dosing of life-saving chemotherapeutics known to cause peripheral neuropathy

Report Objectives & Methodology

In this report, WWMR, Inc., provides an overview of peripheral neuropathy in the seven major pharmaceutical markets:

- U.S.
- Europe
 - France
 - Germany
 - Italy
 - Spain
 - UK
- Japan

Models representing patient populations and the commercial value (USD) of this emerging market through 2012 are presented in a series of tables, charts, and text commentary describing the important features of the key conditions associated with

peripheral neuropathy:

- Diabetes
- HIV/AIDS
- Chemotherapy treatment

Models and commentary describing the current and future peripheral neuropathy market are based on:

- In-depth analysis of the medical literature, including treatment review articles, medical textbooks, epidemiological studies, and clinical trials
- Thorough review of country-specific and overall trends, as well as country-to-country comparisons, of prescriptions written for specific conditions
- Analysis of drugs in the peripheral neuropathy drug pipeline and the future directions in treatment
- Interviews with clinicians, including medical directors of selected pain centers and clinicians treating peripheral neuropathy

WWMR's Worldwide Peripheral Neuropathy report will allow pharmaceutical and biotechnology executives to:

- Recognize the specific conditions associated with peripheral neuropathy that have high market potential in the next 10 years
- Understand the type and level of unmet need in the peripheral neuropathy market in the US, France, Germany, Italy, Spain, UK, and Japan
- Compare the epidemiology of peripheral neuropathy among the 7 major pharmaceutical markets, including projected growth rates
- Target specific patient populations who will benefit most from drugs in the peripheral neuropathy pipeline
- Anticipate upcoming competitors and product licensing opportunities
- Recognize the impact of special market dynamics, including potential off-label usage, on product uptake forecasts
- Develop condition- and country-specific forecasts for major conditions associated with peripheral neuropathy

About EP Publications

Enhance your perspective through EP Publications, a service of WWMR, Inc. Each report pinpoints and evaluates key trends and markets, enabling clients to identify opportunities and augment strategic decisions. In-house consultants with industry experience use qualitative and quantitative research methodologies to provide the most comprehensive and insightful business intelligence available in the life sciences industry.

WPN1103P2



TABLE OF CONTENTS ■ WORLDWIDE PERIPHERAL NEUROPATHY

I. EXECUTIVE SUMMARY

II. INTRODUCTION AND METHODOLOGY

III. PHYSIOLOGY OF PERIPHERAL NEUROPATHY

- A. Definition of Peripheral Neuropathy
 - 1. Nerve Injury
 - 2. Long Duration
 - 3. Abnormal Sensations
 - 4. Aggravation by Physiological Processes
 - 5. Cellular Mechanisms of Neuropathy
- B. Definition of Peripheral Neuropathic Conditions
 - 1. Diabetic Neuropathy
 - 2. Peripheral Neuropathy in HIV/AIDS
 - 3. Chemotherapy-Induced Neuropathy

IV. EPIDEMIOLOGY - CURRENT AND FUTURE

- A. Diabetic Neuropathy
 - 1. Diabetic Neuropathy
 - 2. Diabetes Prevalence
 - 3. Diabetic Neuropathy Prevalence
 - 4. Symptomatic Diabetic Neuropathy Prevalence
 - 5. Diabetic Neuropathy Prevalence
 - 6. Basis for Target Population Projections
 - 7. Seven-Country Diabetic Neuropathy Population Projections
- B. HIV/AIDS Neuropathy
 - 1. HIV/AIDS Neuropathy
 - 2. HIV/AIDS Incidence and Prevalence
 - 3. AIDS Incidence and Prevalence
 - 4. HIV/AIDS Neuropathy Prevalence
 - 5. Basis for Target Population Projections
 - 6. Seven-Country HIV/AIDS Neuropathy Population Projections
- C. Chemotherapy-Induced Neuropathy
 - 1. Chemotherapy-Treated Prevalence
 - 2. Chemotherapy-Induced Neuropathy Prevalence
 - 3. Basis for Target Population Projections
 - 4. Seven-Country Chemotherapy-Induced Neuropathy Population Projections

V. APPROACHES FOR TREATMENT OF PERIPHERAL NEUROPATHY

- A. Actual Clinical Practice and Treatment Limitations
 - 1. Diabetic Neuropathy Treatment
 - 2. HIV/AIDS Neuropathy Treatment
 - 3. Chemotherapy-Induced Neuropathy Treatment
- B. Promising New Approaches
- C. Future Trends
- D. Drugs in Clinical Development to Treat Peripheral Neuropathy
 - 1. Current Clinical Pipeline for Peripheral Neuropathy
 - 1.1 Phase III, Preregistration, Registration and Launched
 - 1.1.1 Aldose Reductase Inhibitors
 - 1.1.2 Carnitine Acetyltransferase Stimulants
 - 1.1.3 Cannabinoid Receptor Agonists
 - 1.1.4 Chemoprotectants
 - 1.1.5 Protein Kinase C Inhibitors
 - 1.2 Phase II
 - 1.2.1 Dopamine Receptor Antagonists
 - 1.2.2 Nerve Growth Factor Agonists
 - 1.2.3 Interleukin-6 Agonists
 - 1.2.4 Prosaposin-Derived Peptide
 - 1.2.5 Prostacyclin Agonists
 - 1.2.6 Prostaglandin E Agonists
 - 1.2.7 Undefined Mechanism
 - 1.2.8 Vascular Endothelial Growth Factor (VEGF)
 - 2. Promising Drugs in Preclinical Development for Peripheral Neuropathy
 - 2.1 Products in Clinical Development for Other Conditions
 - 2.1.1 Copolymer Surfactant
 - 2.1.2 Ion Channel Inhibitors
 - 2.2 Products with No Reported Clinical Development
 - 3. Discontinued or Suspended Drugs

VI. SEVEN-COUNTRY PERIPHERAL NEUROPATHY MARKET FORECAST

- A. Forecast, Methodology, and Assumptions
- B. Diabetic Neuropathy
 - 1. Seven-Country Forecast by Drug Class and Country, 2007 and 2012
- C. HIV/AIDS Neuropathy
 - 1. Seven-Country Forecast by Drug Class and Country, 2007 and 2012
- D. Chemotherapy-Induced Neuropathy
 - 1. Seven-Country Forecast by Drug Class and Country, 2007 and 2012

PARTIAL LIST OF TABLES & FIGURES

- Seven-Country Symptomatic Peripheral Neuropathy Patient Prevalence Projections 2002 – 2012
- Seven-Country Diabetic Neuropathy Population Projections
- Seven-Country HIV/AIDS Neuropathy Projections – HIV Population
- Seven-Country HIV/AIDS Neuropathy Projections – AIDS Population
- Seven-Country Chemotherapy-Induced Peripheral Neuropathy Population Projections
- Summary by Phase of Drugs in Clinical Development for Peripheral Neuropathy
- Seven-Country Prevalence of Peripheral Neuropathy, by Condition, 2002
- Seven-Country Market Forecast, by Class and Country, 2007 and 2012
- Seven-Country Market Forecast, by Condition and Country, 2007 and 2012
- Seven-Country Market Forecast, by Condition and Class, 2007 and 2012